生殖系同源重组缺陷型肝细胞癌的临床基因组特征及合成致死意义
本研究整合本院230例与癌症基因组图谱362例多民族肝细胞癌样本的全外显子或RNA测序数据,分析DNA损伤应答基因的致病性生殖系变异与体细胞变异。96例患者中筛选出110个致病性生殖系变异,其中44例为同源重组相关变异,与肝切除后较差的无病生存独立相关;BRCA2或POLQ缺陷的肝癌细胞对聚腺苷二磷酸核糖聚合酶抑制剂表现出合成致死。
要点
- 肝细胞癌中同源重组相关致病性生殖系变异与肝切除后较差的无病生存独立相关。
- POLQ是生殖系和体细胞组织中最常改变的HR基因,生殖系携带者中占22.7%(10/44),体细胞中占23.8%(5/21)。
- BRCA2或POLQ缺陷的肝癌细胞与PARP抑制剂存在合成致死效应。
核心结论
- 肝细胞癌中的生殖系同源重组缺陷倾向于导致不良预后并形成独特的基因组瘢痕。
- 需要在受影响患者中测试同源重组导向治疗的临床获益。
研究设计与样本
- 研究整合本院(n=230)与癌症基因组图谱(n=362)多民族肝细胞癌样本的全外显子或RNA测序数据。
- 使用选自五个癌症细胞系基因组数据库的肝细胞癌细胞评估靶向同源重组基因突变的合成致死方法。
主要发现
- 共在96例患者中筛选出110个DNA损伤应答通路的致病性生殖系变异。
- 致病性生殖系变异携带者中44例为同源重组相关变异,与肝切除后较差的无病生存独立相关。
- POLQ是生殖系和体细胞组织中最常改变的HR基因,分别见于22.7%(10/44)的生殖系携带者和23.8%(5/21)的体细胞携带者。
- 同源重组相关致病性生殖系变异与增殖和复制相关基因上调及肝细胞癌家族风险显著相关。
- 携带同源重组致病性生殖系变异且伴杂合性缺失的样本与缺陷性同源重组的基因组足迹(如突变负荷和denovoSig2)及不良结局相关性最强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS AND AIMS: We performed an in-depth examination of pathogenic germline variants (PGVs) and somatic variants in DNA damage response (DDR) genes in hepatocellular carcinoma (HCC) to explore their clinical and genomic impacts. APPROACH AND RESULTS: We used a merged whole-exome or RNA sequencing data set derived from in-house ( n = 230) and The Cancer Genome Atlas ( n = 362) databases of multiethnic HCC samples. We also evaluated synthetic lethal approaches targeting mutations in homologous recombination (HR) genes using HCC cells selected from five genomic databases of cancer cell lines. A total of 110 PGVs in DDR pathways in 96 patients were selected. Of the PGV carriers, 44 were HR-altered and found to be independently associated with poorer disease-free survival after hepatectomy. The most frequently altered HR gene in both germline and somatic tissues was POLQ , and this variant was detected in 22.7% (10/44) and 23.8% (5/21) of all the corresponding carriers, respectively. PGVs in HR were significantly associated with upregulation of proliferation and replication-related genes and familial risk of HCC. Samples harboring PGVs in HR with loss of heterozygosity were most strongly correlated with the genomic footprints of deficient HR, such as mutation burden and denovoSig2 (analogous to Catalogue of Somatic Mutations in Cancer [COSMIC] 3), and poor outcome. Pharmacologic experiments with HCC cells defective in BRCA2 or POLQ suggested that tumors with this phenotype are synthetic lethal with poly(ADP-ribose) polymerase inhibitors. CONCLUSIONS: Our findings suggest that germline HR defects in HCC tend to confer a poor prognosis and result in distinctive genomic scarring. Tests of the clinical benefits of HR-directed treatments in the affected patients are needed.
引用
- An J, Oh JH, Oh B, et al. Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient hepatocellular carcinoma. Hepatology. 2022. PMID: 36177702. doi:10.1002/hep.32812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。